Access to Financing Capital by Canadian Innovative Biotechnology Firms - ARCHIVED
Articles and reports: 88F0006X2005010
This paper looks into Canadian innovative biotechnology firms' access to financing capital. Results show that over 70% of biotech firms that attempted to raise financing capital were successful. Funds were primarily sought for R&D activities and came primarily from Canadian venture capitalists. Harsher market conditions were the main reasons put forward by investors to limit or reject biotechnology firms' funding requests.